PCN112 - Metastatic Colorectal Cancer In Croatia - Cost of Disease Study

Abstract

Colorectal cancer is one of the most common cancer sites representing 17% of cancer incidence in males and 8% of cancer incidence in females in Croatia. In 2013, there were 3 070 new cases of colorectal cancer in Croatia and more than 2 000 death cases. The aim of this study was to evaluate resource use and costs associated with the treatment of metastatic colorectal cancer (mCRC) in Croatia in 2013. Publicly available data on the costs related to mCRC treatment were used as input for Markov model with 4 week cycles. The main sources for the number of cases were the Croatian Institute of Public Health Yearbook for 2013 and Croatian Cancer Registry data. For the unit cost list of Diagnosis-Related Groups codes was source. Costs of drugs were taken from national drug reimbursement list. When country-specific information was unavailable, reference to international data was used. Only direct medical costs were taken into consideration, using governmental perspective. In 2013, costs related to mCRC treatment amounted to a total cost of € 47,401,869. Drug costs represent more than 47% of expenditure with a total cost of € 22,432,380. In total drug expenditure 86% were costs for 1st line treatment, 13% for 2nd line and 1% for 3rd line treatment of mCRC. Colorectal cancer represents an important health and economic burden in Croatia. In Croatia it is still diagnosed in late stages with 17% of patients diagnosed with metastatic disease. Results of this study may be usefull to evaluate preventive strategies which have been developed to prevent colorectal cancer and cost associated with this disease.